The Tradr 2X Long CLS Daily ETF seeks to provide twice the daily return of Cresco Labs’ equity performance through the use of derivatives such as total return swaps and other financial instruments, rather than holding the stock directly.
Because leverage is reset daily, performance over periods longer than one trading session can diverge materially from 2x the cumulative return of CLS due to daily compounding effects.

How the Leverage Works
Because the ETF is 2x leveraged on a daily basis:
Over multiple days, returns can vary significantly depending on volatility and the path of price movements, not just the net direction.
Exposure to a High-Beta, Policy-Sensitive Stock
Cresco Labs operates in the U.S. cannabis sector, an industry heavily influenced by:
As a result, CLS often exhibits high daily volatility, which directly impacts the performance—and risk profile—of a 2x leveraged ETF tracking it.
The Tradr 2X Long CLS Daily ETF magnifies both upside and downside moves, making it particularly sensitive to:
Who Should Consider Tradr 2X Long CLS Daily ETF?
This ETF is not designed for buy-and-hold investors. It is best suited for experienced traders who understand leveraged products and monitor positions actively.
Common Use Cases
1.Short-Term Tactical Trading:
Traders with a high-conviction, short-term bullish view on Cresco Labs—perhaps around earnings, regulatory news, or sector momentum—may use the ETF to amplify returns without using margin directly.
2. Event-Driven Positioning:
Investors anticipating near-term catalysts such as earnings surprises, legalization headlines, or sector-wide rallies may deploy the ETF for brief holding periods to express that view.
Key Risks and Strategic Considerations
Before using the Tradr 2X Long CLS Daily ETF, investors should carefully consider:
Price Chart Technical Summary


Conclusion
The Tradr 2X Long CLS Daily ETF is a high-risk, high-reward tactical instrument designed to deliver twice the DAILY performance of Cresco Labs. It is best used by active traders seeking short-term exposure to a volatile, catalyst-driven cannabis stock.
While the ETF can generate outsized gains during strong bullish moves in CLS, it also carries meaningful downside risk and is unsuitable for long-term holding. Proper position sizing, disciplined risk management, and a clear understanding of leveraged ETF mechanics are essential when trading this product.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 22, 2025. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings.
Note 4: ‘Kalkine reports are prepared based on the prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
This report (“Report”) has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any advice provided in this Report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred in this Report. You should obtain a copy of the relevant Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any of the general advice in this Report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.
Kalkine does not issue, sell or deal in any financial products.
This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes. To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Report, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Report or on the Kalkine website. Any such employees and associates are required to comply with certain, procedures and disclosures as required by law.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.
Copyright 2025 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this report, or its content, may be reproduced in any form without our prior consent.
Past performance is not a reliable indicator of future performance.